Nivolumab (Opdivo®)
Dokument
Fact Sheet
Spezifizierung
Nierenzellkarzinom (Hypernephrom)
» + Ipilimumab (Yervoy®)
» fortgeschritten, Erstlinie, intermediäres Risiko
Stand
Mai 2020
Dies ist die aktuell gültige Version des Dokuments
1Nivolumab + Ipilimumab, RCC, advanced, first line, intermediate risk
1 N - number of patients2 RR - remission rate, in %3 PFS - progression-free survival in months5 OS - overall survival in months7 SAE - serious adverse events, CTCAE grade 3/48 results for control, results for new therapy9 hazard ratio for new therapy10 n. s. not significant19 International Metastatic Renal-Cell Carcinoma Database Consortium Score20 International Metastatic Renal-Cell Carcinoma Database Consortium Score
